XNCR News and Press, Xencor Inc. From 10/29/20

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after the market closes on Thursday, November...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer, being ...

Xencor ([[XNCR]] -3.9%) announces safety data from 27 subjects in an ongoing Phase 1 study of evaluating tidutamab (XmAb18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs). The results were presented at the North American Neuroendocrine Tumor So...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced initial data from its ongoing Phase 1 study of tidutamab (XmAb ® 18087), an SSTR2 x CD3 bispec...

Let's face it, today's retail investor is bombarded with information, and parsing through what is useful and what is not can be challenging. Avoiding noise and executing under pressure are critical to investing success. I've been managing custom-built equity portfolios since 2012,...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesda...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that initial data from its ongoing Phase 1 dose-escalation study of tidutamab (XmAb ® 18087), an SSTR2 x...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to study investigational trea...

The following slide deck was published by Xencor, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Xencor Inc (XNCR) Q2 2020 Results Conference Call August 04, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yeng - Chief Medical Officer John Desjarlais - Chief Scientific Officer ...